IL324469A - נוגדנים בי-ספציפיים אנטי-פסאודומונס עם אזורי fc שעברו שינוי ושיטות לשימוש בהם - Google Patents
נוגדנים בי-ספציפיים אנטי-פסאודומונס עם אזורי fc שעברו שינוי ושיטות לשימוש בהםInfo
- Publication number
- IL324469A IL324469A IL324469A IL32446925A IL324469A IL 324469 A IL324469 A IL 324469A IL 324469 A IL324469 A IL 324469A IL 32446925 A IL32446925 A IL 32446925A IL 324469 A IL324469 A IL 324469A
- Authority
- IL
- Israel
- Prior art keywords
- bispecific antibody
- amino acid
- seq
- antibody
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1214—Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363501036P | 2023-05-09 | 2023-05-09 | |
| PCT/EP2024/062700 WO2024231440A1 (en) | 2023-05-09 | 2024-05-08 | Bispecific anti-pseudomonas antibodies with modified fc regions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL324469A true IL324469A (he) | 2026-01-01 |
Family
ID=91082227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL324469A IL324469A (he) | 2023-05-09 | 2024-05-08 | נוגדנים בי-ספציפיים אנטי-פסאודומונס עם אזורי fc שעברו שינוי ושיטות לשימוש בהם |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4709750A1 (he) |
| JP (1) | JP2026518603A (he) |
| KR (1) | KR20260008784A (he) |
| CN (2) | CN121057745A (he) |
| AR (1) | AR132641A1 (he) |
| AU (1) | AU2024269156A1 (he) |
| CL (1) | CL2025003427A1 (he) |
| CO (1) | CO2025016972A2 (he) |
| CR (1) | CR20250521A (he) |
| IL (1) | IL324469A (he) |
| MX (1) | MX2025013179A (he) |
| TW (1) | TW202509059A (he) |
| WO (1) | WO2024231440A1 (he) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| KR20140053410A (ko) | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2013070615A1 (en) | 2011-11-07 | 2013-05-16 | Medlmmune, Llc. | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
| SG11201809778TA (en) * | 2016-05-05 | 2018-12-28 | Univ Pennsylvania | Dna antibody constructs for use against pseudomonas aeruginosa |
| MX2021000889A (es) * | 2018-07-24 | 2021-04-28 | Medimmune Llc | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
-
2024
- 2024-05-08 IL IL324469A patent/IL324469A/he unknown
- 2024-05-08 WO PCT/EP2024/062700 patent/WO2024231440A1/en not_active Ceased
- 2024-05-08 CN CN202480030566.0A patent/CN121057745A/zh active Pending
- 2024-05-08 EP EP24725776.9A patent/EP4709750A1/en active Pending
- 2024-05-08 CN CN202610595918.8A patent/CN122427291A/zh active Pending
- 2024-05-08 KR KR1020257040923A patent/KR20260008784A/ko active Pending
- 2024-05-08 AU AU2024269156A patent/AU2024269156A1/en active Pending
- 2024-05-08 JP JP2025564537A patent/JP2026518603A/ja active Pending
- 2024-05-08 TW TW113117049A patent/TW202509059A/zh unknown
- 2024-05-08 AR ARP240101175A patent/AR132641A1/es unknown
- 2024-05-08 CR CR20250521A patent/CR20250521A/es unknown
-
2025
- 2025-11-04 MX MX2025013179A patent/MX2025013179A/es unknown
- 2025-11-06 CL CL2025003427A patent/CL2025003427A1/es unknown
- 2025-12-04 CO CONC2025/0016972A patent/CO2025016972A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025003427A1 (es) | 2026-02-13 |
| CO2025016972A2 (es) | 2025-12-19 |
| AR132641A1 (es) | 2025-07-16 |
| CN122427291A (zh) | 2026-07-21 |
| JP2026518603A (ja) | 2026-06-09 |
| KR20260008784A (ko) | 2026-01-16 |
| TW202509059A (zh) | 2025-03-01 |
| MX2025013179A (es) | 2025-12-01 |
| AU2024269156A1 (en) | 2026-01-08 |
| EP4709750A1 (en) | 2026-03-18 |
| CR20250521A (es) | 2026-01-14 |
| CN121057745A (zh) | 2025-12-02 |
| WO2024231440A1 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260015420A1 (en) | Cd47 binding agents | |
| US12173067B2 (en) | C-KIT antibodies and method for treating cancer with such | |
| US11773176B2 (en) | Multispecific antibodies, compositions comprising the same, and vectors and uses thereof | |
| JP2025520413A (ja) | FcRn結合分子及び使用方法 | |
| US12528868B2 (en) | CD1a antibodies and uses thereof | |
| TW202346358A (zh) | 經工程改造之cd200r抗體及其用途 | |
| US20240254239A1 (en) | Depletion of activated hepatic stellate cells (hscs) and uses thereof | |
| US20250122288A1 (en) | Fcrn binding molecules and methods of use | |
| AU2017292752A1 (en) | Antibodies with low immunogenicity and uses thereof | |
| US20250326852A1 (en) | Materials and methods for targeting regulatory t cells for enhancing immune surveillance | |
| WO2025140212A1 (en) | Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof | |
| CN112384535A (zh) | 用于治疗慢性荨麻疹的方法和组合物 | |
| US20230227545A1 (en) | Materials and methods of il-1beta binding proteins | |
| TW202509059A (zh) | 具有經修飾Fc區之雙特異性抗假單胞菌抗體及其使用方法 | |
| CN117203230A (zh) | 特异性识别c5a的抗体及其应用 | |
| WO2024160261A1 (en) | Anti-lilrb1 and/or anti-lilrb2 antibodies and uses thereof | |
| KR20260064755A (ko) | 항-acvr2b 항체 및 이의 용도 |